← Back to Search

Monoclonal Antibodies

Module 1: Dose Escalation for Blood Cancers

Phase 1 & 2

Recruiting

Research Sponsored by AstraZeneca

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory

R/R AML

Timeline

Screening 3 weeks

Treatment Varies

Follow Up module 1 - from first dose of azd9829 up to approximately 1 year.

Awards & highlights

Study Summary

This trial is testing a new drug called AZD9829. It will be given through a vein to patients with certain types of blood cancers. The study will determine the best dose of the drug to

Who is the study for?

This trial is for individuals with blood cancers that express a marker called CD123. Specific details about who can join or reasons why someone might not be eligible are not provided.Check my eligibility

What is being tested?

The study is testing AZD9829, given through the vein either alone or with other treatments, to see how it works in treating various blood cancers marked by CD123.See study design

What are the potential side effects?

Potential side effects of AZD9829 are not listed, but as with any cancer treatment, they may include reactions at the infusion site, fatigue, nausea, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My blood cancer tests positive for CD123.

Select...

My condition is relapsed or refractory AML.

Select...

My bone marrow has at least 5% cancer cells.

Select...

I've had one treatment for my current cancer type and have no other treatment options.

Select...

I am 18 years old or older.

Select...

I can take care of myself but might not be able to do heavy physical work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ module 1 - from first dose of azd9829 up to approximately 1 year.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~module 1 - from first dose of azd9829 up to approximately 1 year.

This trial's timeline: 3 weeks for screening, Varies for treatment, and module 1 - from first dose of azd9829 up to approximately 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of dose limiting toxicities (DLTs).

Safety evaluation of AZD9829: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Secondary outcome measures

Complete Response (CR)

Complete remission with incomplete hematologic recovery (CRi)

Composite Complete Response Rate (CCRR)

+16 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Module 1: Dose EscalationExperimental Treatment1 Intervention

Ascending dose level cohorts of AZD9829 in AML and MDS participants.

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

AstraZenecaLead Sponsor

4,271 Previous Clinical Trials

288,612,535 Total Patients Enrolled

1 Trials studying Blood Cancers

32 Patients Enrolled for Blood Cancers

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are patients currently able to participate in this ongoing trial?

"The clinical trial listed on clinicaltrials.gov, posted initially on December 25th, 2023 and last edited on December 19th, 2023, is not currently seeking participants. However, it's worth noting that there are presently 2702 other studies actively enrolling patients."

Answered by AI

Are there a multitude of medical facilities conducting this research within the city?

"At present, enrollment of patients is ongoing at a total of 15 clinical trial sites. These locations include Chapel Hill, Milwaukee, Yoshida-gun, and various other places. It is advisable to choose a clinic in close proximity to minimize travel obligations for potential participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of AZD9829 in CD123+ Hematological Malignancies

2024. "Study of AZD9829 in CD123+ Hematological Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06179511.

All > High Point > Greensboro